Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cook

Showing results (981-990 of 1,031) with videos related to

Pageof 104
Sort By:
International Journal of Cancer|August 28, 2020
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancerPik-Fang Kho, Frederic Amant, Daniela Annibali, et al.
British Journal of Cancer|November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyAshley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Oncotarget|December 3, 2016
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaborationJennifer B Permuth, Brett Reid, Madalene Earp, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|August 1, 2018
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium studyPeter F Rambau, Robert A Vierkant, Maria P Intermaggio, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Cancer Research|December 19, 2018
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer RiskYaohua Yang, Lang Wu, Xiang Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Human Genetics|April 15, 2016
Assessing the genetic architecture of epithelial ovarian cancer histological subtypesGabriel Cuellar-Partida, Yi Lu, Suzanne C Dixon, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Pageof 104

Showing results (981-990 of 1,031) with videos related to

Sort By:
Pageof 104
International Journal of Cancer|August 28, 2020
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancerPik-Fang Kho, Frederic Amant, Daniela Annibali, et al.
British Journal of Cancer|November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyAshley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Oncotarget|December 3, 2016
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaborationJennifer B Permuth, Brett Reid, Madalene Earp, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|August 1, 2018
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium studyPeter F Rambau, Robert A Vierkant, Maria P Intermaggio, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Cancer Research|December 19, 2018
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer RiskYaohua Yang, Lang Wu, Xiang Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Human Genetics|April 15, 2016
Assessing the genetic architecture of epithelial ovarian cancer histological subtypesGabriel Cuellar-Partida, Yi Lu, Suzanne C Dixon, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Pageof 104